| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accelerating research and development of new vaccines against tuberculosis: a global roadmap
|
Cobelens, Frank
|
|
|
22 |
4 |
p. e108-e120
|
artikel
|
| 2 |
A clinical case definition of post-COVID-19 condition by a Delphi consensus
|
Soriano, Joan B
|
|
|
22 |
4 |
p. e102-e107
|
artikel
|
| 3 |
All-cause mortality during the COVID-19 pandemic in Chennai, India: an observational study
|
Lewnard, Joseph A
|
|
|
22 |
4 |
p. 463-472
|
artikel
|
| 4 |
Antibiotic stewardship in the real world
|
Pacios, Enrique
|
|
|
22 |
4 |
p. 448-449
|
artikel
|
| 5 |
Antibiotic stewardship in the real world – Authors' reply
|
van Heijl, Inger
|
|
|
22 |
4 |
p. 449
|
artikel
|
| 6 |
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study
|
Ismail, Nazir Ahmed
|
|
|
22 |
4 |
p. 496-506
|
artikel
|
| 7 |
Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
|
Croda, Julio
|
|
|
22 |
4 |
p. 430-432
|
artikel
|
| 8 |
Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing?
|
Naidoo, Kogieleum
|
|
|
22 |
4 |
p. e121-e127
|
artikel
|
| 9 |
Correction to Lancet Infect Dis 2022; 22: 250–64
|
|
|
|
22 |
4 |
p. e101
|
artikel
|
| 10 |
Correction to Lancet Infect Dis 2022; published online Jan 19. https://doi.org/10.1016/S1473-3099(21)00587-9
|
|
|
|
22 |
4 |
p. e101
|
artikel
|
| 11 |
COVID-19 vaccine results might inform malaria vaccine strategies
|
Abeywickrema, Movin
|
|
|
22 |
4 |
p. 440-441
|
artikel
|
| 12 |
COVID-19 vaccines in the age of the delta variant
|
Wheatley, Adam K
|
|
|
22 |
4 |
p. 429-430
|
artikel
|
| 13 |
Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults
|
Vanshylla, Kanika
|
|
|
22 |
4 |
p. 445-446
|
artikel
|
| 14 |
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses
|
Thiruvengadam, Ramachandran
|
|
|
22 |
4 |
p. 473-482
|
artikel
|
| 15 |
Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India
|
Chakrabarti, Sasanka
|
|
|
22 |
4 |
p. 446-447
|
artikel
|
| 16 |
Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India – Authors' reply
|
Thiruvengadam, Ramachandran
|
|
|
22 |
4 |
p. 447
|
artikel
|
| 17 |
Emerging evidence on heterologous COVID-19 vaccine schedules—To mix or not to mix?
|
Parker, Edward P K
|
|
|
22 |
4 |
p. 438-440
|
artikel
|
| 18 |
Endemic mycoses: geographical distribution is still a work in progress
|
Antinori, Spinello
|
|
|
22 |
4 |
p. 451
|
artikel
|
| 19 |
Endemic mycoses: geographical distribution is still a work in progress – Authors’ reply
|
Le, Thuy
|
|
|
22 |
4 |
p. 451-452
|
artikel
|
| 20 |
Evaluating the risk compensation of HIV/AIDS prevention measures
|
Yan, Xiangyu
|
|
|
22 |
4 |
p. 447-448
|
artikel
|
| 21 |
Global burden and trends of sexually transmitted infections from 1990 to 2019: an observational trend study
|
Zheng, Yang
|
|
|
22 |
4 |
p. 541-551
|
artikel
|
| 22 |
History and evolution of tuberculosis and global health
|
Adhikari, Bipin
|
|
|
22 |
4 |
p. 462
|
artikel
|
| 23 |
Hong Kong's fifth COVID-19 wave—the worst yet
|
Burki, Talha
|
|
|
22 |
4 |
p. 455-456
|
artikel
|
| 24 |
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
|
Zeng, Gang
|
|
|
22 |
4 |
p. 483-495
|
artikel
|
| 25 |
Infectious disease surveillance update
|
Zwizwai, Ruth
|
|
|
22 |
4 |
p. 456
|
artikel
|
| 26 |
Ivermectin for malaria control in mass drug administration programmes
|
Erber, Astrid Christine
|
|
|
22 |
4 |
p. 449-450
|
artikel
|
| 27 |
Ivermectin for malaria control in mass drug administration programmes – Authors' reply
|
Dabira, Edgard D
|
|
|
22 |
4 |
p. 450-451
|
artikel
|
| 28 |
Ivermectin for mass drug administration against malaria
|
Byakika-Kibwika, Pauline
|
|
|
22 |
4 |
p. 433-435
|
artikel
|
| 29 |
Kanta Subbarao—confronting influenza and COVID-19
|
Kirby, Tony
|
|
|
22 |
4 |
p. 460
|
artikel
|
| 30 |
Living with HIV eradication narratives
|
Wortley, Chris
|
|
|
22 |
4 |
p. 461
|
artikel
|
| 31 |
Luc Montagnier
|
Kazi, Farooq
|
|
|
22 |
4 |
p. 458
|
artikel
|
| 32 |
Mass drug administration of ivermectin and dihydroartemisinin–piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia
|
Dabira, Edgard D
|
|
|
22 |
4 |
p. 519-528
|
artikel
|
| 33 |
MMR vaccination in England falls below critical threshold
|
Kirby, Tony
|
|
|
22 |
4 |
p. 453
|
artikel
|
| 34 |
Mortality during the COVID-19 pandemic: the blind spots in statistics
|
Kumar A K, Ajith
|
|
|
22 |
4 |
p. 428-429
|
artikel
|
| 35 |
Oh captain, my captain
|
The Lancet Infectious Diseases,
|
|
|
22 |
4 |
p. 427
|
artikel
|
| 36 |
Pharyngeal screening for Chlamydia trachomatis, more harm than good?
|
van Dam, Alje P
|
|
|
22 |
4 |
p. 437-438
|
artikel
|
| 37 |
Research in brief
|
Devi, Sharmila
|
|
|
22 |
4 |
p. 457
|
artikel
|
| 38 |
Retinitis due to Rickettsia infection
|
Stanescu-Segall, Dinu
|
|
|
22 |
4 |
p. 562
|
artikel
|
| 39 |
Robert Daum
|
Bagcchi, Sanjeet
|
|
|
22 |
4 |
p. 459
|
artikel
|
| 40 |
Routine universal testing versus selective or incidental testing for oropharyngeal Chlamydia trachomatis in women in the Netherlands: a retrospective cohort study
|
Evers, Ymke J
|
|
|
22 |
4 |
p. 552-561
|
artikel
|
| 41 |
Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial
|
Kumar Rai, Ganesh
|
|
|
22 |
4 |
p. 529-540
|
artikel
|
| 42 |
Somalia tackles leprosy and visceral leishmaniasis
|
Bagcchi, Sanjeet
|
|
|
22 |
4 |
p. 454
|
artikel
|
| 43 |
The potential perils of a drug protection framework in tuberculosis
|
Furin, Jennifer
|
|
|
22 |
4 |
p. 432-433
|
artikel
|
| 44 |
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines
|
Gibani, Malick M
|
|
|
22 |
4 |
p. 435-436
|
artikel
|
| 45 |
Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis
|
Dhana, Ashar
|
|
|
22 |
4 |
p. 507-518
|
artikel
|
| 46 |
World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis
|
Ntoumi, Francine
|
|
|
22 |
4 |
p. 442-444
|
artikel
|
Tijdschrift beschrijving